Textainer may look cheap relative to its peers, but you have to steer clear of this stock until the fundamentals start improving," Cramer said. Glenn in Illinois had a question about Celldex Therapeutics, CLDX, a speculative biotech with …
"The consistency of data from three separate studies is impressive and clearly supports the plan to conduct a controlled pivotal study in GBM." Shares of CLDX surged more than 7 percent on the news, with the stock trading at $4.95 ahead …
At some point, however, the stock market will turn and many stocks will turn ... One biotech name that seems to have made the turn is Celldex Therapeutics. Celldex focuses on the development, manufacture and commercialization of …
operating under the Celldex name, according to Miles. CuraGen's stock peaked at $114.25 on the last day of February in 2000. On Oct. 1, the day the Celldex deal closed, one share cost less than a cup of Starbucks coffee — $1.44. …
Both drugs would be likely competitors if approved. The results sent shares of Celldex lower in midday trading. The stock slipped 93 cents, or 14 percent, to $5.63. It has traded between $4.16 and $11.82 over the last 52 weeks.
New York, NY - (ACCESSWIRE) - 11/11/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Gogo Inc. (NASDAQ:GOGO - News), Celldex Therapeutics, Inc. (NASDAQ:CLDX - News), ViroPharma …
Celldex will acquire CuraGen in a tax-free stock-for-stock transaction, which values CuraGen at approximately $94.5 …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLDX at https://www.zacks.com/ap/CLDX Keywords: Celldex
Stock-Callers.com has aligned four equities in the Biotech industry for assessment this morning, and they are Celldex
NEEDHAM, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the …